Bradykinin-mediated diseases - PubMed

Affiliations

• PMID: 24925394
• DOI: 10.1159/000358619

Review

Bradykinin-mediated diseases

Allen P Kaplan. Chem Immunol Allergy. 2014.

Abstract

Diseases which have been demonstrated to be caused by increased plasma levels of bradykinin all have angioedema as the common major clinical manifestation. Angioedema due to therapy with angiotensin-converting enzyme (ACE) inhibitors is caused by suppressed bradykinin degradation so that it accumulates. This occurs because ACE metabolizes bradykinin by removal of Phe-Arg from the C-terminus, which inactivates it. By contrast, angioedema due to C1 inhibitor deficiency (either hereditary types I and II, or acquired) is caused by bradykinin overproduction. C1 inhibitor inhibits factor XIIa, kallikrein and activity associated with the prekallikrein-HK (high-molecular-weight kininogen) complex. In its absence, uncontrolled activation of the plasma bradykinin cascade is seen once there has been an initiating stimulus. C4 levels are low in all types of C1 inhibitor deficiency due to the instability of C1 (C1r, in particular) such that some activated C1 always circulates and depletes C4. In the hereditary disorder, formation of factor XIIf (factor XII fragment) during attacks of swelling causes C4 levels to drop toward zero, and C2 levels decline. A kinin-like molecule, once thought to be a cleavage product derived from C2 that contributes to the increased vascular permeability seen in hereditary angioedema (HAE), is now thought to be an artifact, i.e. no such molecule is demonstrable. The acquired C1 inhibitor deficiency is associated with clonal disorders of B cell hyperreactivity, including lymphoma and monoclonal gammopathy. Most cases have an IgG autoantibody to C1 inhibitor which inactivates it so that the presentation is strikingly similar to type I HAE. New therapies for types I and II HAE include C1 inhibitor replacement therapy, ecallantide, a kallikrein antagonist, and icatibant, a B2 receptor antagonist. A newly described type III HAE has normal C1 inhibitor, although it is thought to be mediated by bradykinin, as is an antihistamine-resistant subpopulation of patients with 'idiopathic' angioedema. The mechanism(s) for the formation of bradykinin in these disorders is unknown.

Similar articles

• Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.

  Kaplan AP, Joseph K. Kaplan AP, et al. Adv Immunol. 2014;121:41-89. doi: 10.1016/B978-0-12-800100-4.00002-7. Adv Immunol. 2014. PMID: 24388213 Review.

• Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

  Kaplan AP, Joseph K. Kaplan AP, et al. Clin Rev Allergy Immunol. 2016 Oct;51(2):207-15. doi: 10.1007/s12016-016-8555-6. Clin Rev Allergy Immunol. 2016. PMID: 27273087 Review.

• Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.

  Joseph K, Tholanikunnel BG, Bygum A, Ghebrehiwet B, Kaplan AP. Joseph K, et al. J Allergy Clin Immunol. 2013 Aug;132(2):470-5. doi: 10.1016/j.jaci.2013.03.026. Epub 2013 May 11. J Allergy Clin Immunol. 2013. PMID: 23672780

• The bradykinin-forming cascade and its role in hereditary angioedema.

  Kaplan AP, Joseph K. Kaplan AP, et al. Ann Allergy Asthma Immunol. 2010 Mar;104(3):193-204. doi: 10.1016/j.anai.2010.01.007. Ann Allergy Asthma Immunol. 2010. PMID: 20377108 Review.

• The plasma bradykinin-forming pathways and its interrelationships with complement.

  Kaplan AP, Ghebrehiwet B. Kaplan AP, et al. Mol Immunol. 2010 Aug;47(13):2161-9. doi: 10.1016/j.molimm.2010.05.010. Mol Immunol. 2010. PMID: 20580091 Review.

Cited by

• A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.

  Ivanov I, Matafonov A, Sun MF, Mohammed BM, Cheng Q, Dickeson SK, Kundu S, Verhamme IM, Gruber A, McCrae K, Gailani D. Ivanov I, et al. Blood. 2019 Mar 7;133(10):1152-1163. doi: 10.1182/blood-2018-06-860270. Epub 2018 Dec 27. Blood. 2019. PMID: 30591525 Free PMC article.

• Kidney tubules: intertubular, vascular, and glomerular cross-talk.

  Ferenbach DA, Bonventre JV. Ferenbach DA, et al. Curr Opin Nephrol Hypertens. 2016 May;25(3):194-202. doi: 10.1097/MNH.0000000000000218. Curr Opin Nephrol Hypertens. 2016. PMID: 27023838 Free PMC article. Review.

• The initiation and effects of plasma contact activation: an overview.

  Lin L, Wu M, Zhao J. Lin L, et al. Int J Hematol. 2017 Mar;105(3):235-243. doi: 10.1007/s12185-016-2132-x. Epub 2016 Nov 15. Int J Hematol. 2017. PMID: 27848184 Review.

• An antibody against HK blocks Alzheimer's disease peptide β-amyloid-induced bradykinin release in human plasma.

  Chen ZL, Singh P, Wong J, Horn K, Strickland S, Norris EH. Chen ZL, et al. Proc Natl Acad Sci U S A. 2019 Nov 12;116(46):22921-22923. doi: 10.1073/pnas.1914831116. Epub 2019 Oct 28. Proc Natl Acad Sci U S A. 2019. PMID: 31659032 Free PMC article.

• Role of Endothelial G Protein-Coupled Receptor Kinase 2 in Angioedema.

  Gambardella J, Sorriento D, Bova M, Rusciano M, Loffredo S, Wang X, Petraroli A, Carucci L, Mormile I, Oliveti M, Bruno Morelli M, Fiordelisi A, Spadaro G, Campiglia P, Sala M, Trimarco B, Iaccarino G, Santulli G, Ciccarelli M. Gambardella J, et al. Hypertension. 2020 Nov;76(5):1625-1636. doi: 10.1161/HYPERTENSIONAHA.120.15130. Epub 2020 Sep 8. Hypertension. 2020. PMID: 32895019 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • S. Karger AG, Basel, Switzerland

• Other Literature Sources

  • scite Smart Citations

• Miscellaneous

  • NCI CPTAC Assay Portal